Adial Pharmaceuticals, Inc. Accrued Liabilities for Commissions, Expense and Taxes
Adial Pharmaceuticals, Inc. (ADIL) had Accrued Liabilities for Commissions, Expense and Taxes of $11.02 thousand as of 2023-03-31, per its 10-Q filed 2023-05-12.
Discontinued › Notes › Financial Services › Insurance
us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes · last filed 2023-05-12
- 2023-03-31: Accrued Liabilities for Commissions, Expense and Taxes $11.02K.
| Period end | Accrued Liabilities for Commissions, Expense and Taxes |
|---|---|
| 2023-03-31 | $11.02K 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |